RXRX vs. VCEL, PTCT, APGE, KYMR, ADMA, ACLX, BEAM, TWST, IMCR, and SANA
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Vericel (VCEL), PTC Therapeutics (PTCT), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), ADMA Biologics (ADMA), Arcellx (ACLX), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Immunocore (IMCR), and Sana Biotechnology (SANA). These companies are all part of the "medical" sector.
Vericel (NASDAQ:VCEL) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Vericel has higher revenue and earnings than Recursion Pharmaceuticals. Vericel is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vericel has a net margin of 0.22% compared to Vericel's net margin of -765.90%. Recursion Pharmaceuticals' return on equity of 0.21% beat Vericel's return on equity.
Vericel has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Vericel received 315 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 62.22% of users gave Vericel an outperform vote while only 51.22% of users gave Recursion Pharmaceuticals an outperform vote.
In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Vericel. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 7 mentions for Vericel. Recursion Pharmaceuticals' average media sentiment score of 0.48 beat Vericel's score of 0.45 indicating that Vericel is being referred to more favorably in the media.
Vericel currently has a consensus price target of $46.80, suggesting a potential downside of 3.21%. Recursion Pharmaceuticals has a consensus price target of $12.75, suggesting a potential upside of 35.35%. Given Vericel's higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Vericel.
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Vericel beats Recursion Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
